PARP Inhibitors in Pancreatic Cancer: Experts Discuss Importance Of Testing For Biomarkers Along With Current Treatment Landscape: Podcast Pearls

In this downloadable PDF summary from a CCO podcast, Philip Philip, MD, PhD and Elena Chiorean, MD discuss the role of biomarker testing and PARP inhibitors in the treatment of pancreatic cancer.
Elena Gabriela Chiorean, MD
Philip Agop Philip, MD, PhD, FRCP
Format: Adobe Acrobat (.pdf)
File Size: 182 KB
Released: November 3, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca

Related Content

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers

Rachna Shroff, MD Released: January 21, 2022

On-demand video roundtable of global experts’ perspectives on optimal management of pancreatic cancer with PARP inhibitors, from Clinical Care Options (CCO)

Downloadable slideset on current advances in PARP inhibition in pancreatic cancer from Clinical Care Options (CCO)

Dirk Arnold, MD, PhD person default Michel Ducreux, MD, PhD Philip Agop Philip, MD, PhD, FRCP Released: December 14, 2021

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings